Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rene A Braeckman

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Clinical Drug Investigation|April 25, 2014
Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parametersRene A Braeckman, William G Stirtan, Paresh N Soni
Clinical Pharmacology in Drug Development|June 23, 2015
Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy SubjectsRene A Braeckman, William G Stirtan, Paresh N Soni
Expert Opinion on Pharmacotherapy|May 25, 2013
Icosapent ethyl for the treatment of hypertriglyceridemiaChristie M Ballantyne, Rene A Braeckman, Paresh N Soni
Clinical Drug Investigation|December 5, 2014
Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatinRene A Braeckman, William G Stirtan, Paresh N Soni
Drugs in R&D|June 29, 2014
Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adultsRene A Braeckman, William G Stirtan, Paresh N Soni
Clinical Pharmacology in Drug Development|June 23, 2015
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy SubjectsRene A Braeckman, William G Stirtan, Paresh N Soni
The American Journal of Cardiology|January 16, 2013
Authors' replyChristie M Ballantyne, Harold E Bays, Rene A Braeckman, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|September 3, 2013
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)Rene A Braeckman, Mehar S Manku, Harold E Bays, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 18, 2013
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studiesHarold E Bays, Christie M Ballantyne, Rene A Braeckman, et al.
Cardiovascular Diabetology|July 10, 2013
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR studyEliot A Brinton, Christie M Ballantyne, Harold E Bays, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Clinical Drug Investigation|April 25, 2014
Phase 1 study of the effect of icosapent ethyl on warfarin pharmacokinetic and anticoagulation parametersRene A Braeckman, William G Stirtan, Paresh N Soni
Clinical Pharmacology in Drug Development|June 23, 2015
Pharmacokinetics of Eicosapentaenoic Acid in Plasma and Red Blood Cells After Multiple Oral Dosing With Icosapent Ethyl in Healthy SubjectsRene A Braeckman, William G Stirtan, Paresh N Soni
Expert Opinion on Pharmacotherapy|May 25, 2013
Icosapent ethyl for the treatment of hypertriglyceridemiaChristie M Ballantyne, Rene A Braeckman, Paresh N Soni
Clinical Drug Investigation|December 5, 2014
Effect of concomitant icosapent ethyl (eicosapentaenoic acid ethyl ester) on the pharmacokinetics of atorvastatinRene A Braeckman, William G Stirtan, Paresh N Soni
Drugs in R&D|June 29, 2014
Effect of icosapent ethyl (eicosapentaenoic acid ethyl ester) on omeprazole plasma pharmacokinetics in healthy adultsRene A Braeckman, William G Stirtan, Paresh N Soni
Clinical Pharmacology in Drug Development|June 23, 2015
Effects of Icosapent Ethyl (Eicosapentaenoic Acid Ethyl Ester) on Pharmacokinetic Parameters of Rosiglitazone in Healthy SubjectsRene A Braeckman, William G Stirtan, Paresh N Soni
The American Journal of Cardiology|January 16, 2013
Authors' replyChristie M Ballantyne, Harold E Bays, Rene A Braeckman, et al.
Prostaglandins, Leukotrienes, and Essential Fatty Acids|September 3, 2013
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study)Rene A Braeckman, Mehar S Manku, Harold E Bays, et al.
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|January 18, 2013
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studiesHarold E Bays, Christie M Ballantyne, Rene A Braeckman, et al.
Cardiovascular Diabetology|July 10, 2013
Effects of icosapent ethyl on lipid and inflammatory parameters in patients with diabetes mellitus-2, residual elevated triglycerides (200-500 mg/dL), and on statin therapy at LDL-C goal: the ANCHOR studyEliot A Brinton, Christie M Ballantyne, Harold E Bays, et al.
Pageof 2